Trends & Insights
News
Search
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Livestock
Livestock
Business Resource Groups at Boehringer Ingelheim
Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US
Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.
Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US
Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.
Pulmonary Fibrosis
Pulmonary fibrosis is a condition leading to a build-up of scar tissue in the lungs. Over time, the lungs lose their ability to take in and transfer oxygen into the bloodstream.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
Our People, Our Culture
Our People, Our Culture
FDA Grants BTD for Investigational Treatment of CIAS | BI US
Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
From garbage to garden - Recycling organic waste to contribute to a healthier planet
From garbage to garden - Recycling organic waste to contribute to a healthier planet
Patients with a rare and aggressive form of liposarcoma need treatment advances
Patients with a rare and aggressive form of liposarcoma need treatment advances
Our Partners: University of Georgia USA
Our Partners: University of Georgia USA
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Words of Health and Hope
Click here to hear from our patients, who have expressed to us in beautifully written thank you notes for our BI Cares Patient Assistance Program.
Terms of Use
Terms of Use
The Core of our Leitbild
Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.
Terms of Use
Terms of Use
Oncology & Cancer Immunology
Oncology & Cancer Immunology